Literature DB >> 19782080

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

William O Osburn1, Brian E Fisher, Kimberly A Dowd, Giselle Urban, Lin Liu, Stuart C Ray, David L Thomas, Andrea L Cox.   

Abstract

BACKGROUND & AIMS: We followed patients with ongoing hepatitis C virus (HCV) exposure following control of an initial HCV infection to determine whether primary control conferred protection against future persistent infections.
METHODS: Twenty-two active injection drug users (IDU) who had cleared a primary hepatitis C viremia for at least 60 days were monitored monthly. Reinfection was defined as the detection of a new HCV infection. Protection was assessed based on the magnitude and duration of viremia following reinfection and generation of T-cell and neutralizing antibody (nAb) responses.
RESULTS: Reinfection occurred in 11 IDU (50%) who previously spontaneously controlled primary HCV infection. Although viral clearance occurs in approximately 25% of patients with primary infections, spontaneous viral clearance was observed in 83% of reinfected patients. The duration and maximum level of viremia during subsequent episodes of reinfection were significantly decreased compared with those of the primary infection in the same subjects. In contrast to chronic infection, reinfection was associated with a significant increase in the breadth of T-cell responses. During acute infection, nAbs against heterologous viral pseudoparticles were detected in 60% of reinfected subjects; cross-reactive nAbs are rarely detected in patients who progress to chronic infection.
CONCLUSIONS: HCV reinfection is associated with a reduction in the magnitude and duration of viremia (compared with the initial infection), broadened cellular immune responses, and generation of cross-reactive humoral responses. These findings are consistent with development of adaptive immunity that is not sterilizing but protects against chronic disease. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782080      PMCID: PMC2889495          DOI: 10.1053/j.gastro.2009.09.017

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

Review 1.  The chimpanzee model of hepatitis C virus infections.

Authors:  R E Lanford; C Bigger; S Bassett; G Klimpel
Journal:  ILAR J       Date:  2001

2.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

3.  Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection.

Authors:  S E Bassett; B Guerra; K Brasky; E Miskovsky; M Houghton; G R Klimpel; R E Lanford
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

5.  Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees.

Authors:  Michelina Nascimbeni; Eishiro Mizukoshi; Markus Bosmann; Marian E Major; Kathleen Mihalik; Charles M Rice; Stephen M Feinstone; Barbara Rehermann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.

Authors:  F Lechner; N H Gruener; S Urbani; J Uggeri; T Santantonio; A R Kammer; A Cerny; R Phillips; C Ferrari; G R Pape; P Klenerman
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

7.  Cross-genotype immunity to hepatitis C virus.

Authors:  Robert E Lanford; Bernadette Guerra; Deborah Chavez; Catherine Bigger; Kathleen M Brasky; Xiao-Hong Wang; Stuart C Ray; David L Thomas
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  170 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

3.  Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

Authors:  Desarae Echevarria; Alexander Gutfraind; Basmattee Boodram; Jennifer Layden; Jonathan Ozik; Kimberly Page; Scott J Cotler; Marian Major; Harel Dahari
Journal:  Vaccine       Date:  2019-04-05       Impact factor: 3.641

4.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

5.  Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks.

Authors:  Rebecca Rose; Christopher Rodriguez; James Jarad Dollar; Susanna L Lamers; Guido Massaccesi; William Osburn; Stuart C Ray; David L Thomas; Andrea L Cox; Oliver Laeyendecker
Journal:  Infect Genet Evol       Date:  2019-02-22       Impact factor: 3.342

Review 6.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

7.  Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.

Authors:  Naga Suresh Veerapu; Sukanya Raghuraman; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

8.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 9.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

10.  T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use.

Authors:  Eveli Kallas; Kristi Huik; Silver Türk; Merit Pauskar; Ene-Ly Jõgeda; Marina Šunina; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Radko Avi; Irja Lutsar
Journal:  Viral Immunol       Date:  2016-08-26       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.